Related Experiment Video
Updated: Feb 19, 2026
04:41
Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
19.5K
[Personal genomics for Alzheimer's disease]
1Department of Molecular Genetics, Niigata University, Japan.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|March 12, 2013
Summary
Alzheimer's disease (AD) genetics are complex, with APOE being a major risk factor for late-onset AD (LOAD). New sequencing technologies are crucial for identifying additional AD risk genes beyond APOE.
Area of Science:
- Neuroscience
- Genetics
- Gerontology
Context:
- Alzheimer's disease (AD) is the leading cause of dementia in older adults.
- Early-onset AD (ADEOAD) has known genetic links (APP, PSEN1, PSEN2), but late-onset AD (LOAD) is more common and complex.
- The apolipoprotein E (APOE) gene is the strongest known risk factor for LOAD, yet it doesn't explain all cases.
Purpose:
- To explore genetic factors contributing to Alzheimer's disease, particularly LOAD.
- To investigate the limitations of previous genetic studies (GWAS) in identifying AD risk genes.
- To highlight the potential of advanced sequencing technologies for discovering novel AD-related genes.
Summary:
- While APP, PSEN1, and PSEN2 genes are linked to early-onset AD, many LOAD cases lack the APOE ε4 risk allele, suggesting other genetic factors.
- Genome-wide association studies (GWAS) have not identified additional risk genes with the same impact as APOE.
- Recent advances in whole genome and exome sequencing are revealing new causative genes for familial LOAD and sporadic early-onset AD (EOAD).
Impact:
- Personal genome sequencing offers a promising strategy to identify both risk and protective genes for Alzheimer's disease.
- Understanding the genetic architecture of AD beyond APOE is critical for developing effective diagnostics and therapeutics.
- This research paves the way for personalized medicine approaches in Alzheimer's disease based on an individual's genetic profile.
More Related Videos
09:34Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
34.9K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.8K
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
25
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
25
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
18
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18
01:26Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
01:28Human Genetics
1.7K
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
1.7K
01:22Alzheimer's Disease: Treatment
1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
01:11Genome-wide Association Studies-GWAS
15.8K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.8K